Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment
Regimen selection was associated with baseline disease severity and inflammatory burden. Despite being used in patients with more advanced profiles, BIC/F/TAF effectively reduced systemic inflammation over 2 years. Both regimens attenuated inflammatory activity, though with distinct trajectories that may carry implications for immune recovery and long-term outcomes.
Authors
- Inés Suárez‐García (ORCID: https://orcid.org/0000-0002-7016-716X)
- Elena Moreno (ORCID: https://orcid.org/0000-0002-2301-4558)
- Robert Güerri‐Fernández (ORCID: https://orcid.org/0000-0002-9794-9161)
- Javier Martínez‐Sanz (ORCID: https://orcid.org/0000-0003-2020-3908)
- Juncal Pérez‐Somarriba (ORCID: https://orcid.org/0000-0002-9623-5781)
- Sergio Serrano‐Villar (ORCID: https://orcid.org/0000-0002-5447-3554)
- David Dalmau Juanola
- C. Vanesa Díaz-García (ORCID: https://orcid.org/0000-0001-7570-7113)
- Santiago Moreno (ORCID: https://orcid.org/0000-0002-2843-1094)
- Alejandro García García (ORCID: https://orcid.org/0000-0003-4896-6528)
- Cristina Hernández Gutiérrez
- Sonsoles Sánchez Palomino
Institutions
- Foundation for Biomedical Research (US)
- Universitat Pompeu Fabra (ES)
- Universidad de Alcalá (ES)
- Instituto Cajal (ES)
- Instituto de Salud Carlos III (ES)
- Hospital Clínico San Carlos (ES)
- Universidad Nebrija (ES)
- Universidad Europea (MX)
- Hospital Universitario Príncipe de Asturias (ES)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Clínic de Barcelona (ES)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Mútua Terrassa (ES)
- Hospital Del Mar (ES)
- Biomedical Research Foundation (BD)
- Hospital Universitario Infanta Sofía (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1093/ofid/ofaf626
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences
- Ministerio de Ciencia e Innovación
- Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina
- Instituto de Salud Carlos III